Ep. 6: Should the FDA Be Independent? episode artwork

EPISODE · Sep 9, 2025 · 1H 41M

Ep. 6: Should the FDA Be Independent?

from Drug Dealin · host Drug Dealin Pod

SUMMARY: In this episode, Shivu and Kenny discuss the recent developments surrounding Replimune and its interactions with the FDA. They explore the implications of leadership changes at the FDA, the importance of patient advocacy, and the challenges faced by small biotech companies in navigating the regulatory landscape. The conversation highlights the critical role of stability in drug approvals and the potential impact on patient care, particularly in oncology. They discuss the complexities of the FDA's role in drug development, the importance of confirmatory studies, and the impact of leadership changes on regulatory processes. They also talk about the historical evolution of the FDA, its commitment to patient safety, and the challenges it faces in maintaining consistency and transparency. The conversation culminates in a thought-provoking discussion on the potential benefits of an independent FDA, akin to the Federal Reserve, to enhance trust and efficacy in drug approvals.DISCLAIMER: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.CHAPTERS:00:00 The FDA's Independence and Scope02:53 Timeline of Instability at the FDA14:00 Impact of Instability on Drug Development19:54 Case Study: RepliMune's Regulatory Journey34:00 Navigating FDA Interactions and Accelerated Approvals58:03 The Role of a Healthy FDA: History and Function01:12:40 Organizational Culture and Stability in Regulatory Agencies01:15:24 Navigating Institutional Changes at the FDA01:18:45 The Importance of Consistency in Health Guidelines01:22:27 Transparency and Data Disclosure in Drug Approvals01:25:18 The Case for an Independent FDA01:29:53 Lessons from the Federal Reserve's Independence01:35:11 Engendering Trust in Health Institutions01:41:49 Final ThoughtsCONTACT US:Questions?: ⁠⁠[email protected]⁠⁠Follow us on X Follow Shivu on XSubscribe to Shivu's newsletter, Big Pharma Sharma ⁠⁠Follow Kenny

SUMMARY: In this episode, Shivu and Kenny discuss the recent developments surrounding Replimune and its interactions with the FDA. They explore the implications of leadership changes at the FDA, the importance of patient advocacy, and the challenges faced by small biotech companies in navigating the regulatory landscape. The conversation highlights the critical role of stability in drug approvals and the potential impact on patient care, particularly in oncology. They discuss the complexities of the FDA's role in drug development, the importance of confirmatory studies, and the impact of leadership changes on regulatory processes. They also talk about the historical evolution of the FDA, its commitment to patient safety, and the challenges it faces in maintaining consistency and transparency. The conversation culminates in a thought-provoking discussion on the potential benefits of an independent FDA, akin to the Federal Reserve, to enhance trust and efficacy in drug approvals.DISCLAIMER: The views and opinions expressed in this podcast are for informational and educational purposes only. They are not intended as medical advice and should not be used as a substitute for professional medical judgment or guidance. Always consult a qualified healthcare provider with any questions you may have regarding a medical condition or treatment.CHAPTERS:00:00 The FDA's Independence and Scope02:53 Timeline of Instability at the FDA14:00 Impact of Instability on Drug Development19:54 Case Study: RepliMune's Regulatory Journey34:00 Navigating FDA Interactions and Accelerated Approvals58:03 The Role of a Healthy FDA: History and Function01:12:40 Organizational Culture and Stability in Regulatory Agencies01:15:24 Navigating Institutional Changes at the FDA01:18:45 The Importance of Consistency in Health Guidelines01:22:27 Transparency and Data Disclosure in Drug Approvals01:25:18 The Case for an Independent FDA01:29:53 Lessons from the Federal Reserve's Independence01:35:11 Engendering Trust in Health Institutions01:41:49 Final ThoughtsCONTACT US:Questions?: ⁠⁠[email protected]⁠⁠Follow us on X Follow Shivu on XSubscribe to Shivu's newsletter, Big Pharma Sharma ⁠⁠Follow Kenny

NOW PLAYING

Ep. 6: Should the FDA Be Independent?

0:00 1:41:59

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Drug Dealin?

This episode is 1 hour and 41 minutes long.

When was this Drug Dealin episode published?

This episode was published on September 9, 2025.

What is this episode about?

SUMMARY: In this episode, Shivu and Kenny discuss the recent developments surrounding Replimune and its interactions with the FDA. They explore the implications of leadership changes at the FDA, the importance of patient advocacy, and the challenges...

Can I download this Drug Dealin episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!